Weight loss drug ozempic tested in lung disease patients

NCT ID NCT05746039

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This pilot study tests whether semaglutide (Ozempic), a drug used for diabetes and obesity, is safe and tolerable for weight loss in people with advanced lung disease. Eight participants with conditions like COPD or pulmonary fibrosis will take weekly injections for 12 weeks. Researchers will monitor side effects, weight, and lung function to see if the drug can be used in this fragile group.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
semaglutide (Ozempic)
What this could lead to
If it works, this could show that semaglutide is a safe option for weight loss in people with advanced lung disease, potentially improving their quality of life.
What could go wrong
This is a very small pilot study with only 8 participants, so results may not apply to everyone. Side effects like nausea or vomiting could be worse in people with lung problems.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CHRONIC OBSTRUCTIVE PULMONARY DISEASE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • University of Pennsylvania Perelman School of Medicine

    RECRUITING

    Philadelphia, Pennsylvania, 19104, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.